Pathos AI, Inc. (www.pathos.com) announced today that it has entered into a worldwide license agreement to develop FT-7051, a small molecule CBP/p300 inhibitor program from Novo Nordisk as Pathos’ ...
CHICAGO, Aug. 15, 2024 (GLOBE NEWSWIRE) -- Pathos AI, Inc. (www.pathos.com), a biotechnology company focused on revolutionizing precision medicine in cancer by harnessing the power of machine learning ...
NEW YORK, May 08, 2025 (GLOBE NEWSWIRE) -- Pathos AI, a leading AI-enabled biotech company focused on transforming drug development in oncology, today announced the appointment of Iker Huerga as Chief ...
New York-based Pathos AI, a biotech company applying artificial intelligence (AI) to drug development, has announced a $365 million Series D financing, bringing its post-money valuation to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback